PTPI (Petros Pharmaceuticals) Days Payable: 0.00 (As of Mar. 2026)

What is Petros Pharmaceuticals Days Payable?

Petros Pharmaceuticals PTPI -1.07% Days Payable is 0.00 as of Mar. 2026. Among 923 Drug Manufacturers companies, Petros Pharmaceuticals ranks worse than 108342.25% on this metric.

Petros Pharmaceuticals's average Accounts Payable for the three months ended in Mar. 2026 was $0.11 Mil. Petros Pharmaceuticals's Cost of Goods Sold for the three months ended in Mar. 2026 was $0.00 Mil.

The historical rank and industry rank for Petros Pharmaceuticals's Days Payable or its related term are showing as below:

During the past 7 years, Petros Pharmaceuticals's highest Days Payable was 1160.51. The lowest was 185.57. And the median was 408.57.

PTPI's Days Payable is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 90.98
* Ranked among companies with meaningful Days Payable only.

Petros Pharmaceuticals's Days Payable stayed the same from Mar. 2025 (0.00) to Mar. 2026 (0.00). stayed the same

Petros Pharmaceuticals Days Payable Related Terms

Petros Pharmaceuticals Days Payable Historical Data

* Premium members only.

The historical data trend for Petros Pharmaceuticals's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Petros Pharmaceuticals Days Payable Chart

Petros Pharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Days Payable

Get a 7-Day Free Trial

1,160.51

507.40

393.76

372.67

0.00

Petros Pharmaceuticals Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Days Payable	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

PTPI vs GCAN, KOAN, PNXP: Days Payable Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Petros Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Petros Pharmaceuticals Days Payable vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Petros Pharmaceuticals's Days Payable distribution charts can be found below:

* The bar in red indicates where Petros Pharmaceuticals's Days Payable falls into.

Save Embed

Petros Pharmaceuticals Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Petros Pharmaceuticals's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as

	Days Payable (A: Dec. 2025 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2024 )	+	Accounts Payable (A: Dec. 2025 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2025 )	*	Days in Period
=	( (0.764	+	0.084)	/	2 )	/	0	*	365
=	0.424					/	0	*	365
=	N/A

Petros Pharmaceuticals's Days Payable for the quarter that ended in Mar. 2026 is calculated as:

	Days Payable (Q: Mar. 2026 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Dec. 2025 )	+	Accounts Payable (Q: Mar. 2026 ))	/	count )	/	Cost of Goods Sold (Q: Mar. 2026 )	*	Days in Period
=	( (0.084	+	0.133)	/	2 )	/	0	*	365 / 4
=	0.1085					/	0	*	365 / 4
=	N/A

Frequently Asked Questions Learn more about Days Payable →

What does a Days Payable of 0.00 mean?

Petros Pharmaceuticals (PTPI) has a Days Payable of 0.00 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Petros Pharmaceuticals and its competitors. Over the past decade, Petros Pharmaceuticals' Days Payable has ranged from 185.57 to 1,160.51. According to the industry distribution chart, Petros Pharmaceuticals ranks #999999 out of 923 companies in the Drug Manufacturers industry.

Is Petros Pharmaceuticals' Days Payable too high?

Petros Pharmaceuticals' current Days Payable is 0.00. Over the past 10 years, this metric has ranged from a low of 185.57 to a high of 1,160.51. Based on the distribution chart, Petros Pharmaceuticals ranks #999999 out of 923 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.

How does Petros Pharmaceuticals' Days Payable compare to GCAN and KOAN?

According to the Drug Manufacturers industry distribution chart, Petros Pharmaceuticals ranks #999999 out of 923 companies for Days Payable. This places Petros Pharmaceuticals in the lower half of its industry. The industry median Days Payable is 90.98. Historically, Petros Pharmaceuticals' own Days Payable has ranged from 185.57 to 1,160.51 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Days Payable for a Drug Manufacturers company?

The median Days Payable among Drug Manufacturers companies is 90.98, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Days Payable mean?

A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Petros Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Petros Pharmaceuticals's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Petros Pharmaceuticals stock overvalued right now?

Petros Pharmaceuticals (PTPI) has a current Days Payable of 0.00. The current Days Payable is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Days Payable calculated?

Days Payable is calculated from a company's financial statements. For Petros Pharmaceuticals (PTPI), the current Days Payable is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Petros Pharmaceuticals Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies GCAN KOAN PNXP STEK OWPC NPHC PLSH CBDY XTER:MRK TSE:4502 XSWX:GALD SHSE:600276 NSE:SUNPHARMA XTAE:TEVA LSE:HLN XSWX:SDZ ZTS HKSE:03692 UTHR VTRS

Address 1185 Avenue of the Americas, 3rd Floor, New York, NY, USA, 10036

Website https://www.petrospharma.com

Petros Pharmaceuticals Inc is a men's health pharmaceutical company. The Company is working towards the goal of becoming an innovator in the emerging self-care market, driving expanded access to key nonprescription pharmaceuticals as Over-the-Counter and nonprescription drug products with additional conditions for nonprescription use (ACNU Products) treatment options. Petros is pursuing the development of a proprietary integrated technology solutions platform containing two components: SaaS, designed to assist pharmaceutical companies in operationalizing and commercializing an Rx-to-OTC switch as an element in the development of an ACNU Product, and a potential Software as a Medical Device component, which guides the consumer in navigating appropriate self-selection or deselection.